RCEL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 Jul 2024 @ 00:33):
Our systems believe the stock currently is undervalued by 0.04% compare to its pairs and should correct upwards.

Stats
今日成交量	62 737
平均成交量	289 341
市值	200.21M
EPS	$-0.530 ( Q3 \| 2023-11-09 )
下一个收益日期	( $-0.590 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.41 (Sector) 42.63 (Industry) 0
ATR14	$0.0290 (0.37%)

AEMD -4.56%

AFIB -12.68%

AHCO -3.30%

AHPI 0.00%

ALGN -0.53%

ANIK 2.40%

APEN 0.00%

APYX 2.24%

ARAY -3.30%

ATEC -4.98%

AXDX -3.42%

AXGN 5.39%

AXNX 0.06%

AZYO 2.05%

BBLG -1.62%

BIOL 20.00%

BJDX -0.59%

BMRA 4.55%

BRKR -2.76%

BSGM -2.88%

BWAY -2.86%

CERS 0.00%

CFMS 0.44%

CLPT 1.76%

CODX -1.62%

CSII 0.15%

CTKB -0.27%

CTSO 4.57%

CUTR 0.00%

CVRX -5.84%

DCTH -1.79%

DXCM -1.11%

DYNT -0.04%

EAR -4.10%

ECOR -2.33%

EDAP -2.94%

ESTA -4.64%

FONR 1.13%

HJLI -1.98%

HSDT -0.06%

HSKA 0.00%

HYPR 3.65%

IART -0.40%

ICAD -0.38%

ICCM -2.57%

IINN -9.43%

INGN -2.46%

INMD -0.93%

IRIX -0.36%

IRMD -1.64%

IRTC -2.24%

ISO 0.00%

ITMR 0.00%

KIDS -3.34%

LHDX 0.00%

LIVN 0.07%

LNSR -2.33%

LUCD -3.54%

LUNG -2.37%

MASS -5.83%

MDGS 10.28%

MOTS 16.31%

MOVE 5.13%

MSON 0.00%

NAOV 3.54%

NARI 2.47%

NMRD 33.33%

NNOX -2.85%

NPCE 0.66%

NTUS 0.00%

NURO 0.81%

NUVA -2.24%

NUWE -13.16%

NVCN 0.00%

NVNO -1.52%

OBLN -5.86%

OFIX -1.92%

OM -4.29%

PACB -7.31%

PAVM -1.96%

PETV -23.08%

PODD -1.71%

PRCT 0.87%

PROF 1.15%

QIPT -2.17%

QTRX -5.22%

RCEL -2.02%

RPID 2.80%

RSLS 0.89%

RWLK 6.07%

RXST -2.31%

SGHT -3.15%

SIBN -0.85%

SIEN -18.69%

SILK -0.06%

SINT -3.95%

SOLY 0.00%

SRDX -0.08%

SRGA 0.00%

SRTS -5.44%

SWAV 0.00%

TBIO 12.06%

TCMD -2.85%

TELA -2.34%

THMO 9.52%

TIVC 0.52%

TLIS -1.99%

TMCI -1.50%

TMDI 0.00%

TMDX 0.18%

TNDM -3.70%

TNON 17.77%

UFPT 4.98%

VERO -5.42%

VIVE 0.00%

VMD -2.29%

VRAY 0.00%

VREX -2.13%

VVOS 3.15%

XAIR 5.16%

XENT 0.00%

ZIMV 0.11%

Insider Trading

Date	Person	Action	Amount	type
2024-06-05	Panaccio Lou	Buy	9 200	Common Stock
2024-06-05	Panaccio Lou	Buy	3 943	Stock Options (Right to Buy)
2024-06-05	Crowe Suzanne	Buy	9 200	Common Stock
2024-06-05	Crowe Suzanne	Buy	3 943	Stock Options (Right to Buy)
2024-06-05	Cook Jeremy Curnock	Buy	9 200	Common Stock

INSIDER POWER
85.50
Last 98 transactions
Buy: 1 898 967 \| Sell: 352 272

相关性 (AI algo v.1.1b): Undervalued: 0.04% $7.76 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.04 (neutral)

短: -0.39 (neutral)

Signal:(43.068) Neutral

Avita Therapeutics Inc 相关性

10 最正相关
LSXMA	0.926
CTSH	0.922
LSXMK	0.922
INVE	0.908
FSV	0.9
BRZE	0.899
ZD	0.892
MBIO	0.892
BMEA	0.888
MPAA	0.884

10 最负相关
PAAS	-0.969
AMRK	-0.953
CRIS	-0.932
VERU	-0.922
ABIO	-0.919
HYMC	-0.917
RING	-0.909
CENX	-0.902
FSLR	-0.901
GRIN	-0.898

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Avita Therapeutics Inc 相关性 - 货币/商品

-0.37
( neutral )

0.26
( neutral )

0.00
( neutral )

0.23
( neutral )

-0.05
( neutral )

0.03
( neutral )

Avita Therapeutics Inc 财务报表

Annual	2022
营收:	$34.42M
毛利润:	$28.38M (82.45 %)
EPS:	$-1.070

FY	2022
营收:	$34.42M
毛利润:	$28.38M (82.45 %)
EPS:	$-1.070

FY	2021
营收:	$29.23M
毛利润:	$23.28M (79.65 %)
EPS:	$-1.170

FY	2020
营收:	$14.26M
毛利润:	$11.29M (79.16 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Avita Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avita Therapeutics Inc

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.